US Stock MarketDetailed Quotes

MNPR Monopar Therapeutics

Watchlist

0.7272
+0.0672+10.18%

Close May 3 16:00 ET

0.7290
+0.0018+0.25%

Post 19:11 ET

12.69MMarket Cap-1192P/E (TTM)

Monopar Therapeutics Stock Forum

Trytosaveabit

Apr 16 20:03

Update

$Monopar Therapeutics(MNPR.US)$ Monopar Announces Filing of Patent Protecting Mnpr-101 Radiopharma Optimization Findings

NASSER09

Apr 11 22:49

$Monopar Therapeutics(MNPR.US)$
🔥💯💯💯👌👌👌👌
im rich

102261387

Apr 11 20:59

$Monopar Therapeutics(MNPR.US)$ Monopar Therapeutics Inc (MNPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading upgraded the rating on the stock to a Buy and gave it a $2.00 price target.

Trytosaveabit

Apr 10 20:03

Update

$Monopar Therapeutics(MNPR.US)$ Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE

FattyChick

Mar 5 20:02

$Monopar Therapeutics(MNPR.US)$ Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

71825221

Feb 27 21:44

BITCOIN (BTCUSD) STRONG BUY ALERT 🚨🚨

I love me

Feb 23 23:32

$Monopar Therapeutics (MNPR.US)$ great I buy uvas this morning at 1.90 and shit dumps to 1.05 lowest alltime loss of 40% then I come here at 1.66 and now it dumps like wtf

102261387

Feb 23 23:11

$Monopar Therapeutics(MNPR.US)$

Trytosaveabit

Feb 23 20:09

Nice bounce

$Monopar Therapeutics(MNPR.US)$

Stock Region

Feb 23 07:47

Monopar Therapeutics Announces Significant Preclinical Data for MNPR-101 Radiopharma Program Targeting Advanced Cancers.

Monopar Therapeutics Inc., an innovative clinical-stage biopharmaceutical company, recently announced promising preclinical data for its MNPR-101 Radiopharma Program. The program is specifically designed to target advanced cancers, offering hope for millions of patients worldwide. $Monopar Therapeutics(MNPR.US)$
https://stockregion.app/p/therapeutics-company-announces-promising

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

Concept

Top Gainers Yesterday

Intraday+1.62%